Welcome to our dedicated page for Neuronetics SEC filings (Ticker: STIM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Neuronetics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Neuronetics's regulatory disclosures and financial reporting.
Neuronetics, Inc. executive William Andrew Macan, EVP, CLO and CS, reported a small automatic share sale tied to equity compensation. On March 4, 2026, he disposed of 609 shares of common stock in open-market transactions at a weighted average price of $1.34 per share, with individual prices ranging from $1.28 to $1.39. The footnotes state these were non-discretionary sales made solely to satisfy his tax withholding obligation upon the vesting of a restricted stock unit award. After this tax-related sale, he continued to own 879,525 common shares directly.
Madryn-affiliated investment funds report a major stake in Neuronetics, Inc., holding 20,737,061 shares of common stock, or about 30.3% of the company. These percentages are based on 68,485,922 shares outstanding as of October 29, 2025, from Neuronetics’ Form 10-Q.
The filing describes a Registration Rights Agreement, as amended, giving Madryn parties registration and piggyback rights for their consideration shares. Madryn has agreed not to acquire additional Neuronetics equity or convertible debt and to vote all of its shares at the 2026 annual meeting in line with the board’s recommendations on specified proposals.
STIM filed a Form 144 notifying proposed sales of common stock by an insider. The notice lists proposed transactions tied to restricted stock vesting and identifies prior open-market dispositions by William A. Macan of 3,485, 14,120, and 3,427 common shares on 02/10/2026, 02/12/2026, and 02/26/2026, respectively.
The filing names Fidelity Brokerage Services LLC as broker and records an entry dated 03/04/2026 on NASDAQ. The Form indicates securities arising from restricted stock vesting dated 02/27/2026 and labels the grant as compensation.
Neuronetics, Inc. entered into a Second Amendment to its Registration Rights Agreement with Madryn Asset Management and its affiliates. The amendment updates how Neuronetics will handle potential future resale registrations of Neuronetics shares held by the Madryn parties and adds a voting commitment.
Under the amendment, if Neuronetics receives a Shelf Notice after the amendment becomes effective, it must prepare and file a registration statement for resale of all Registrable Securities then beneficially owned by the Madryn parties as promptly as practicable and within five business days after filing its Form 10‑K for the year ended December 31, 2025. The Madryn parties also agree to vote all Neuronetics shares they own at the 2026 annual meeting in line with the Board of Directors’ voting recommendations on certain proposals defined in the amendment.
Neuronetics, Inc. executive William Andrew Macan, EVP, CLO and CS, reported an open-market sale of 3,427 shares of common stock at a weighted average price of $1.35 per share. The sale was a non-discretionary transaction to cover tax withholding upon vesting of a restricted stock unit award, and he now holds 880,134 shares directly.
Neuronetics, Inc. President and CEO Keith J. Sullivan reported an open-market sale of 8,452 shares of common stock at a reported weighted average price of $1.35 per share. According to the filing, these were non-discretionary sales to satisfy tax withholding obligations upon vesting of a restricted stock unit award. After the transaction, Sullivan directly owned 1,524,713 shares of Neuronetics common stock.
Keith Sullivan reported insider sales of common stock. The filing lists 8,452 shares classified as securities to be sold following 02/24/2026 vesting as compensation. The filing also discloses sales of 40,976 shares on 02/10/2026 and 33,847 shares on 02/12/2026, with dollar amounts shown alongside each sale.
STIM files a Form 144 notice to sell Common shares. The notice lists 3,427 shares under "Securities To Be Sold" tied to Restricted Stock Vesting on 02/24/2026. The filing also reports prior sales by William A. Macan of 3,485 shares on 02/10/2026 and 14,120 shares on 02/12/2026.
Neuronetics, Inc. reported that its Board and Compensation Committee approved annual cash incentive awards for three senior executives. On February 23, 2026, the Compensation Committee approved cash incentives of $73,216.44 for Executive Vice President and Chief Financial Officer Steven E. Pfanstiel and $163,383.75 for Executive Vice President, Chief Legal Officer, and Corporate Secretary W. Andrew Macan.
On the same date, the Board, following the Compensation Committee’s recommendation, approved an annual cash incentive award of $412,775.95 for President and Chief Executive Officer Keith J. Sullivan. The company stated that these cash incentive awards will be paid on or about March 13, 2026.
Neuronetics, Inc. reported that EVP, CFO and Treasurer Steven Pfanstiel acquired an award of 250,000 shares of common stock in the form of restricted stock units. The award was granted at no purchase price.
The RSUs vest in three equal annual installments beginning on February 23, 2027, as long as he remains in continuous service through each vesting date. After this grant, his directly held common stock position reported in the filing totals 820,212 shares.